Manu Vandijck

3.2k total citations · 1 hit paper
29 papers, 904 citations indexed

About

Manu Vandijck is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Manu Vandijck has authored 29 papers receiving a total of 904 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Physiology, 14 papers in Psychiatry and Mental health and 9 papers in Molecular Biology. Recurrent topics in Manu Vandijck's work include Alzheimer's disease research and treatments (26 papers), Dementia and Cognitive Impairment Research (14 papers) and Metabolomics and Mass Spectrometry Studies (4 papers). Manu Vandijck is often cited by papers focused on Alzheimer's disease research and treatments (26 papers), Dementia and Cognitive Impairment Research (14 papers) and Metabolomics and Mass Spectrometry Studies (4 papers). Manu Vandijck collaborates with scholars based in Belgium, United States and Sweden. Manu Vandijck's co-authors include Kaj Blennow, Erik Stoops, Henrik Zetterberg, Anne M. Fagan, Eugeen Vanmechelen, Hugo Vanderstichele, Oskar Hansson, Nicholas J. Ashton, Jeroen Vanbrabant and Gallen Triana‐Baltzer and has published in prestigious journals such as Brain, Neurology and Scientific Reports.

In The Last Decade

Manu Vandijck

29 papers receiving 883 citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

2022 242 citations Shorena Janelidze, Nicholas J. Ashton et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manu Vandijck Belgium	11	660	559	189	165	119	29	904
Wagner S. Brum Brazil	16	700 1.1×	561 1.0×	209 1.1×	173 1.0×	96 0.8×	37	1.0k
Ashvini Keshavan United Kingdom	18	589 0.9×	410 0.7×	209 1.1×	192 1.2×	181 1.5×	38	976
Jeroen Vanbrabant Belgium	10	603 0.9×	484 0.9×	184 1.0×	165 1.0×	100 0.8×	22	800
Carole Ho United States	5	400 0.6×	409 0.7×	186 1.0×	152 0.9×	132 1.1×	8	964
Olga Pletnikova United States	12	527 0.8×	414 0.7×	226 1.2×	210 1.3×	163 1.4×	17	958
Marwan Sabbagh United States	8	432 0.7×	349 0.6×	218 1.2×	154 0.9×	131 1.1×	13	927
Katharina Zink Germany	3	561 0.8×	549 1.0×	142 0.8×	175 1.1×	65 0.5×	5	795
Evert J. van Elk Netherlands	10	743 1.1×	698 1.2×	217 1.1×	233 1.4×	106 0.9×	10	1.0k
Joakim Hertze Sweden	10	661 1.0×	434 0.8×	235 1.2×	321 1.9×	143 1.2×	11	990
Francesco Garaci Italy	17	595 0.9×	278 0.5×	285 1.5×	162 1.0×	149 1.3×	25	1.1k

Countries citing papers authored by Manu Vandijck

Since Specialization

Citations

This map shows the geographic impact of Manu Vandijck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manu Vandijck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manu Vandijck more than expected).

Fields of papers citing papers by Manu Vandijck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manu Vandijck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manu Vandijck. The network helps show where Manu Vandijck may publish in the future.

Co-authorship network of co-authors of Manu Vandijck

This figure shows the co-authorship network connecting the top 25 collaborators of Manu Vandijck. A scholar is included among the top collaborators of Manu Vandijck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manu Vandijck. Manu Vandijck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Verberk, Inge M.W., Mardou van Leeuwenstijn, Wiesje M. van der Flier, et al.. (2025). Evidence‐based standardized sample handling protocol for accurate blood‐based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium. Alzheimer s & Dementia. 21(10). e70752–e70752. 1 indexed citations

Vanbrabant, Jeroen, Sherif Bayoumy, Nathalie Le Bastard, et al.. (2024). Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217. Alzheimer s Research & Therapy. 16(1). 266–266. 4 indexed citations

Vandijck, Manu, et al.. (2023). Preliminary performance of the Lumipulse G pTau 217 Plasma prototype assay on plasma samples. Alzheimer s & Dementia. 19(S15). 3 indexed citations

Öhrfelt, Annika, Andréa Lessa Benedet, Nicholas J. Ashton, et al.. (2022). Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals. Neurology. 100(3). e275–e285. 19 indexed citations

Simone, F., et al.. (2022). Reducing misdiagnosis of Alzheimer’s Disease pathology utilizing CSF and amyloid PET. Alzheimer s & Dementia. 18(S5). 1 indexed citations

Nojima, Hisashi, Satoshi Itō, Aki Abe, et al.. (2022). Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE^® system. Annals of Clinical and Translational Neurology. 9(12). 1898–1909. 9 indexed citations

Vandijck, Manu, et al.. (2022). Analytical performance overview of the Lumipulse G pTau 181 Plasma RUO. Alzheimer s & Dementia. 18(S6). 1 indexed citations

Moon, Sohee, Sujin Kim, Sakulrat Mankhong, et al.. (2021). Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans. Alzheimer s Research & Therapy. 13(1). 22–22. 15 indexed citations

Sandelius, Åsa, Markus Axelsson, Clas Malmeström, et al.. (2019). Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis. Scientific Reports. 9(1). 17309–17309. 3 indexed citations

10.

Sandelius, Åsa, Nicholas Cullen, Lars Rosengren, et al.. (2018). Transient increase in CSF GAP-43 concentration after ischemic stroke. BMC Neurology. 18(1). 202–202. 24 indexed citations

11.

Hansson, Oskar, Alvydas Mikulskis, Anne M. Fagan, et al.. (2018). The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimer s & Dementia. 14(10). 1313–1333. 91 indexed citations

12.

Andréasson, Ulf, Josef Pannee, Robert M. Umek, et al.. (2018). Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements. Clinical Chemistry and Laboratory Medicine (CCLM). 56(12). 2058–2066. 27 indexed citations

13.

Vandijck, Manu, et al.. (2018). P1‐276: ANALYTICAL PERFORMANCE OF A FULLY AUTOMATED CHEMILUMINESCENT β‐AMYLOID 1‐40 ASSAY ON THE LUMIPULSE G SERIES. Alzheimer s & Dementia. 14(7S_Part_7). 1 indexed citations

14.

Vandijck, Manu, et al.. (2015). P1‐116: Correlation of the modified innotest β‐amyloid _1‐42 with a lc‐ms/ms candidate reference method. Alzheimer s & Dementia. 11(7S_Part_8). 2 indexed citations

15.

Lachno, D. Richard, et al.. (2015). Validation and Clinical Utility of ELISA Methods for Quantification of Amyloid-β Peptides in Cerebrospinal Fluid Specimens from Alzheimer's Disease Studies. Journal of Alzheimer s Disease. 45(2). 527–542. 11 indexed citations

16.

Sutphen, Courtney L., Mateusz S. Jasielec, Aarti R. Shah, et al.. (2015). Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurology. 72(9). 1029–1029. 224 indexed citations

17.

Darby, Heather, Manu Vandijck, Hilde Decraemer, et al.. (2014). P4‐037: IMPROVEMENTS TO INNOTEST® PHOSPHO‐TAU 181P. Alzheimer s & Dementia. 10(4S_Part_22). 2 indexed citations

18.

Vandijck, Manu, et al.. (2014). P1‐159: IMPROVEMENTS TO INNOTEST® B‐AMYLOID 1‐42. Alzheimer s & Dementia. 10(4S_Part_9). 1 indexed citations

19.

Vandijck, Manu, Ryozo Kuwano, Teresa Waligórska, et al.. (2013). P1–166: Inter‐laboratory variation when using a unified test procedure for INNO‐BIA AlzBio3. Alzheimer s & Dementia. 9(4S_Part_5). 5 indexed citations

20.

Carrillo, María C., Kaj Blennow, Holly Soares, et al.. (2012). Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimer s & Dementia. 9(2). 137–140. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact